ClinicalTrials.gg
Not yet recruitingNCT07839143Updated Sep 24, 2026

A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Clinical Trial Evaluating the Safety and Efficacy of Single-use Peripheral Intravascular Shock Wave Catheters Combined With Intravascular Shock Wave Therapy Devices for Peripheral Artery Calcified Lesions.

An interventional study of Interventional therapy in the experimental group and Interventional therapy in the control group in Patients With Peripheral Artery Calcified Lesions, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This trial is a prospective, multicenter, randomized, parallel controlled clinical trial. It to recruit patients with peripheral arterial calcified lesions, who will be randomly assigned in a 1:1 ratio to either the group or the control group. Subjects in the experimental group will use a disposable intra-peripheral vascularwave catheter combined with an intravascular shockwave therapy device to treat peripheral arterial calcified lesions and perform balloon dilation, while subjects in the control group will use a peripheral balloon dilation catheter to treat peripheral arterial calcified lesions and perform balloon dilation.

02

Conditions studied

  • Patients With Peripheral Artery Calcified Lesions
03

In context

Lead sponsor

Shanghai Bluesail Boyuan Medical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

General selection criteria

  1. Age 18 to 80 years old, regardless of gender;
  2. Rutherford grade is 2 to 5
  3. As judged by the investigator, peripheral endovascular treatment is required;
  4. The subject or their legal guardian has been informed of the purpose of the trial, consents to participate and signs the form;
  5. The subject is willing comply with all assessment requirements in the trial;

Inclusion criteria for angiography:

1) Target lesions are vascular calcified lesions of grade Ⅲ to Ⅳ according to PARC classification: 2 Target lesions are located in native femoral artery and/or popliteal artery; 3) Total of target lesion ≤260mm; if it contains occlusive lesion, length of occlusive segment ≤100mm and total length of target lesion ≤20mm; 4) Target lesions have not undergone any surgical interventions including endovascular therapy and open surgery before, and the stenosis degree target lesion is ≥70% (visual assessment); 5) Reference vessel diameter of target is between 2.5mm and 8.0mm; 6) At least one distal outflow tract of target lesion is (vascular stenosis degree ≤50% by visual assessment), with blood flow reaching foot (not dependent on collateral circulation); or the patient has successfully undergone treatment for target lesion before (i.e., residual stenosis degree ≤30% by visual assessment after treatment, without serious complications); 7) The ipsilateral inflow tract of target lesion is patent (vascular stenosis degree ≤50% by visual assessment), or the patient has successfully undergone treatment for lesion before (i.e., residual stenosis degree ≤30% by visual assessment treatment, without serious complications);

Exclusion Criteria:

General Exclusion Criteria

  1. History of amputation of target limb or planned major amputation (above the ankle
  2. > 3 or count \< 60×10\^9/L;
  3. Patients with known renal insufficiency (ser creatinine >2.5 mg/dL or 220 μmol/L) or renal failure requiring long-term dialysis;
  4. Patients with known to antiplatelet andagulant therapy;
  5. Patients with known allergies to contrast agents used in endovascular therapy and experimental device materials;
  6. Patients who have receivedbolytic therapy in the target vessel within 14 days prior to signing informed consent; ) Patients who have experienced myocardial infarction within 60 days prior to signing informed consent;

8) Patients who have experienced stroke within 60 days prior to signing informed consent; 9) Women of childbearing age who are pregnant, breastfeeding or planning pregnancy; 10) Patients participating in other medical device or drug clinical trials; 11) Other reasons considered by the investigator as inappropriate for participation in the trial.

Angiography exclusion criteria:

  1. The target vessel has evidence of aneurysm or acute/chronic thrombosis;
  2. The vessel is highly tortuous (the visual arc is greater than 30°);
  3. The guidewire cannot pass through the target lesion; 4 There is in-stent restenosis in the target lesion area;

5) Before treating the lesion with research devices, ablative devices such as cutting balloons, scoring balloons, compliant balloons, mammillary balloons, pronged balloons, plaque excision devices, excimer laser systems, and peripheral throm aspiration catheters need to be used.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
158 participants (estimated)

Study arms

  • Experimental
    experimental group

    The subjects in the experimental group used disposable peripheral intravascular shockwave catheters with intravascular shockwave therapy devices to treat peripheral artery calcification lesions and perform balloon dilatation.

    Procedure: Interventional therapy in the experimental group

  • Experimental
    control group

    The subjects in the control group used peripheral balloon dilatation catheters to treat artery calcified lesions and conduct balloon dilatation.

    Procedure: Interventional therapy in the control group

Interventions

  • ProcedureInterventional therapy in the experimental group

    The subjects in the experimental group used disposable peripheral intravascular shockwave catheters combined with intravascular shockwave therapy devices to treat peripheral artery calcification lesions and perform balloon dilatation.

  • ProcedureInterventional therapy in the control group

    The subjects in the control group used peripheral balloon dilatation catheters to treat peripheral artery calcified lesions and conduct balloon dilatation.

06

What researchers measure

Primary outcomes

  1. Technical success rate

    After treatment with the investigational device, residual diameter stenosis of the target lesion is ≤0% and no dissection of grade ≥D is present.

    Time frame: immediately after surgery

Secondary outcomes

  1. Device success rate

    The interventional device successfully reached the lesion site, achieved successful expansion without any rupture, was successfully withdrawn.

    Time frame: immediately after surgery

  2. Primary patency rate of target lesions at 30 days after operation

    No clinically driven target lesion revascularization (CD-TLR) and no target lesionosis detected by imaging examinations

    Time frame: 30 days after operation

  3. Changes in ankle-brachial index at 7 days postoperatively or on the day discharge, and at 30 days postoperatively.

    Time frame: 7 days post-operation or the day of discharge, 30 days post-operation

  4. Changes in Rutherford grade at 7 days postoperatively or discharge day, 3 days postoperatively, and 6 months postoperatively

    Changes in Rutherford grade at 7 days postoperatively or discharge day, 3 days postoperatively, and 6 months postoperatively

    Time frame: 7 days after surgery or discharge date, 30 days after surgery, 6 months surgery

  5. Incidence rate of clinically driven target lesion revascularization (CD-TLR) at30 days and 6 months after surgery

    Incidence rate of clinically driven target lesion revascularization (CD-TLR) at30 days and 6 months after surgery

    Time frame: 30 days after surgery, 6 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 24, 2026
StartEst.
Sep 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07839143
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Lu Xinwu Principal Investigator
Contact
luxw1654@sh9hospital.org.cn
86-21-23271699

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion